Matritech and Bayer in cervical test tie-up
This article was originally published in Clinica
Executive Summary
Bayer will gain the rights to develop new cervical cancer detection systems based on Matritech's patented Nuclear Matrix Protein (NMP) technology under a product development and marketing option agreement just signed with the US based company. In return, Matritech would receive an initial payment plus further milestone and option payments. If Bayer's US Diagnostics Division exercises its marketing option, it will have the exclusive worldwide right to sell automated NMP-based cervical cancer systems utilising raw materials supplied by its new partner.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.